Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Familial Haploidentical Stem Cell Transplant in Children and Adolescents With High-Risk Sickle Cell Disease: A Phase 2 Clinical Trial. JAMA Pediatr 2020 Feb 01;174(2):195-197

Date

12/10/2019

Pubmed ID

31816036

Pubmed Central ID

PMC6902105

DOI

10.1001/jamapediatrics.2019.4715

Scopus ID

2-s2.0-85076336992 (requires institutional sign-in at Scopus site)   28 Citations

Abstract

This phase 2 clinical trial in patients with high-risk sickle cell disease assesses the feasibility, safety, and 1-year event-free survival after myeloimmunoablative conditioning and familial haploidentical stem cell transplant.

Author List

Cairo MS, Talano JA, Moore TB, Shi Q, Weinberg RS, Grossman B, Shenoy S

Author

Julie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Anemia, Sickle Cell
Child
Child, Preschool
Female
Humans
Male
Prospective Studies
Risk Assessment
Stem Cell Transplantation
Young Adult